Basic Search
|
Summaries
|
Advanced Search
Violation Tracker UK Individual Case
Company: Actavis UK Ltd.
Current Parent Company:
Intas Pharmaceuticals Ltd.
Parent at the Time of the Penalty Announcement: Actavis PLC
Recap of Ownership Changes: Actavis PLC had acquired Allergan Inc. and changed name to Allergan PLC in 2015. Later in 2016 they sold Actavis UK Ltd. to Teva Pharmaceutical Industries, which sold Actavis UK to Accord Healthcare, a subsidiary of Intas Pharmaceuticals, in 2017.
Penalty: £1,542,860
Year: 2016
Date: 12 February, 2016
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: Actavis UK Limited (formerly Alpharma Limited) was fined £1,542,860 in a decision by the CMA that the company accepted money from GlaxoSmithKline to delay entry into the UK market with the generic drug paroxetine (allowing GSKs branded version Seroxat to dominate the market at a higher price), in breach of competition law.
Action Type: agency action
Agency: Competition and Markets Authority
HQ Country of Parent: India
Ownership Structure of Parent: privately held
Major Industry of Parent: pharmaceuticals
Specific Industry of Parent: pharmaceuticals
Source of Data:
(click here)
